Up to 24% of the EU and USA population suffer from Chronic Constipation. The most affected collectives are women, aging elderly people and patients with Neurogenic Bowel disorders related to Spinal Cord Injury, Parkinson and Multiple Sclerosis. Constipation causes a painful evacuation, fecal impaction and fecal incontinence, which have a big negative impact on the quality of life of these patients.
USMIMA S.L. created in 2014, offers MOWOOT, a non-pharmacological, non-invasive solution to relieve chronic constipation, without side-effects, in form of a wearable class II medical device that automatically emulates the abdominal massage techniques of professional therapists via a number series of actuators.
A pilot study with chronically constipated patients had already shown that the daily use of MOWOOT ameliorates idiopathic chronic constipation.
USMIMA wants to target a 90B M€ market of 250 million people with chronic constipation identified.
A feasibility study showed that, in order to target this market and increase the influence on target clients, USMIMA had to prioritize the following activities during the project:
• Conduct a larger clinical study as a marketing strategy to build confidence in the medical sector and promote MOWOOT prescriptions and reimbursement
• Reduce costs (below current 500€) through re-design and preparation of scaling the manufacturing process
• Upgrade Mowoot 1.0 prototype to Mowoot 2.0 product, by adding cloud and smart services and other features required by users and professionals
MOWOOT will empower patients and elderly people, enhance well-being among the society, increase autonomy of the treatment and reduce the increasing health care expenses due to aging population and the derived long-term cares.
